BioNTech SE Sponsored ADR (NASDAQ:BNTX) Position Reduced by Deutsche Bank AG

Deutsche Bank AG trimmed its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 4.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 289,788 shares of the company's stock after selling 14,712 shares during the quarter. Deutsche Bank AG owned about 0.12% of BioNTech worth $26,388,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Capital International Investors lifted its stake in shares of BioNTech by 38.6% in the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company's stock worth $161,304,000 after acquiring an additional 394,434 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of BioNTech by 18,892.9% during the first quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after buying an additional 694,691 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of BioNTech during the fourth quarter worth about $69,999,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in BioNTech by 632.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock valued at $57,191,000 after purchasing an additional 433,388 shares during the period. Finally, Braidwell LP grew its holdings in BioNTech by 25.1% in the fourth quarter. Braidwell LP now owns 309,865 shares of the company's stock valued at $35,309,000 after purchasing an additional 62,115 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Price Performance

NASDAQ BNTX traded up $0.82 on Friday, reaching $113.52. The company's stock had a trading volume of 501,363 shares, compared to its average volume of 694,543. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The stock has a market cap of $27.29 billion, a PE ratio of -70.95 and a beta of 1.23. The firm's 50 day moving average is $109.42 and its two-hundred day moving average is $105.81.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm had revenue of $306.46 million for the quarter, compared to analysts' expectations of $161.26 million. During the same period in the prior year, the company posted ($3.36) earnings per share. BioNTech's quarterly revenue was up 102.6% compared to the same quarter last year. As a group, sell-side analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Leerink Partners set a $112.00 price target on shares of BioNTech in a research report on Monday, June 2nd. HC Wainwright cut their price target on shares of BioNTech from $138.00 to $136.00 and set a "buy" rating on the stock in a report on Thursday. Morgan Stanley boosted their target price on shares of BioNTech from $132.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. Finally, Wall Street Zen upgraded shares of BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $135.80.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.